PIK3CA E545X
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene PIK3CA
Variant E545X
Impact List missense
Protein Effect unknown
Gene Variant Descriptions PIK3CA E545X indicates any Pik3ca missense mutation that results in the replacement of the glutamic acid (E) at amino acid 545 by a different amino acid. PIK3CA E545X mutations are hotspot mutations that may result in increased Pik3ca kinase activity (PMID: 15930273).
Associated Drug Resistance
Category Variants Paths

PIK3CA mutant PIK3CA exon10 PIK3CA E545X

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_006218.4
gDNA chr3:g.179218303_179218305
cDNA c.1633_1635
Protein p.E545
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_006218.3 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
XM_011512894 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
NM_006218 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
XM_006713658.4 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
NM_006218.4 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
XM_006713658 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
XM_011512894.2 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38
XM_006713658.5 chr3:g.179218303_179218305 c.1633_1635 p.E545 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03842228 Phase I Copanlisib + Durvalumab + Olaparib Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Active, not recruiting USA 0
NCT04586335 Phase I CYH33 + Olaparib Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Terminated USA | AUS 1